Travis Hoium

GLP-1s are going to be a topic.

And speaking of those GLP-1s, they're not all great for even the pharmaceutical companies.

We'll get to that in a moment.

You're listening to Motley Fool Money.

Welcome back to Motley Fool Money.

The GLP-1 craze was started by Eli Lilly and Novo Nordisk, are really the two companies that are associated with this.

But Rachel, Novo Nordisk took a huge hit in the market, and they're actually expecting a decline in the business.

What is the story behind this?

It seems like GLP-1 should be just growing forever, but it seems like the competitive dynamics are really changing there.

There's more coming to the market over the next couple of years, too.

Again, another thing that is going to be fascinating to follow because this has been a huge growth story for a number of different companies and a lot of speculation behind some of the new GOP ones that are coming.

But yeah, like Lou said, if you're coming into a very competitive market, maybe it's not the best to be those producers which are having margin pressure, even if you have higher volume.

As always, people on the program may have interest in the stocks they talk about, and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear.

All personal finance content follows The Motley Fool's editorial standards and is not approved by advertisers.

Advertisements are sponsored content and provided for informational purposes only.

To see our full advertising disclosure, please check out our show notes.

For Lou Whiteman, Rachel Warren, Dan Boyd, and Christy Waterworth behind the glass, I'm Travis William.

We'll see you here tomorrow.

Well, if you're Elon Musk, that's certainly the narrative you're trying to sell.

And there really is a positive way to view the investments that Musk and team are making between these companies, right?